# Kyverna Therapeutics, Inc.: financial statements, quarterly

KYTX · Nasdaq · CIK 1994702 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/kytx.md) · [Financials](/companies/kytx/financials.md) · [Filings](/companies/kytx/filings.md) · [Insiders](/companies/kytx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/kytx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [13.6](/filings/0000950170-24-126366.md) | [17.2 d](/filings/0000950170-25-046074.md) | [22.5](/filings/0000950170-25-070325.md) | [27.3](/filings/0000950170-25-107321.md) | [29.2](/filings/0001193125-25-277584.md) | [33.5 d](/filings/0001193125-26-126242.md) | [37.4](/filings/0001193125-26-219397.md) | [35.8](/filings/0001193125-26-344607.md) | [30.5](/filings/0001193125-25-277584.md) | [30.0 d](/filings/0001193125-26-126242.md) | [30.1](/filings/0001193125-26-219397.md) | [24.8](/filings/0001193125-26-344607.md) |
| Operating income | $m | [(16.3)](/filings/0000950170-24-126366.md) | [(21.4) d](/filings/0000950170-25-046074.md) | [(29.4)](/filings/0000950170-25-070325.md) | [(33.4)](/filings/0000950170-25-107321.md) | [(38.8)](/filings/0001193125-25-277584.md) | [(41.0) d](/filings/0001193125-26-126242.md) | [(47.4)](/filings/0001193125-26-219397.md) | [(44.4)](/filings/0001193125-26-344607.md) | [(38.7)](/filings/0001193125-25-277584.md) | [(39.3) d](/filings/0001193125-26-126242.md) | [(41.4)](/filings/0001193125-26-219397.md) | [(39.6)](/filings/0001193125-26-344607.md) |
| Interest expense | $m | [0.1](/filings/0000950170-24-126366.md) | [0.0 d](/filings/0000950170-25-046074.md) | [0.0](/filings/0000950170-24-059628.md) | [0.0](/filings/0000950170-24-095462.md) | [0.0](/filings/0001193125-25-277584.md) | [0.0 d](/filings/0001193125-26-126242.md) | [0.0](/filings/0001193125-26-219397.md) | [0.0](/filings/0001193125-26-344607.md) | [0.0](/filings/0001193125-25-277584.md) | [0.4 d](/filings/0001193125-26-126242.md) | [0.7](/filings/0001193125-26-219397.md) | [0.7](/filings/0001193125-26-344607.md) |
| Net income | $m | [(15.5)](/filings/0000950170-24-126366.md) | [(20.7) d](/filings/0000950170-25-046074.md) | [(26.7)](/filings/0001193125-25-277584.md) | [(28.8)](/filings/0001193125-25-277584.md) | [(34.5)](/filings/0001193125-25-277584.md) | [(37.5) d](/filings/0001193125-26-126242.md) | [(44.6)](/filings/0001193125-26-344607.md) | [(42.1)](/filings/0001193125-26-344607.md) | [(36.8)](/filings/0001193125-25-277584.md) | [(37.8) d](/filings/0001193125-26-126242.md) | [(39.7)](/filings/0001193125-26-344607.md) | [(38.3)](/filings/0001193125-26-344607.md) |
| Diluted EPS | $ per share | [(23.27)](/filings/0000950170-24-126366.md) | not reported | [(1.12)](/filings/0000950170-25-070325.md) | [(0.67)](/filings/0000950170-25-107321.md) | [(0.80)](/filings/0001193125-25-277584.md) | not reported | [(1.03)](/filings/0001193125-26-219397.md) | [(0.97)](/filings/0001193125-26-344607.md) | [(0.85)](/filings/0001193125-25-277584.md) | not reported | [(0.66)](/filings/0001193125-26-219397.md) | [(0.63)](/filings/0001193125-26-344607.md) |
| Basic EPS | $ per share | [(23.27)](/filings/0000950170-24-126366.md) | not reported | [(1.12)](/filings/0000950170-25-070325.md) | [(0.67)](/filings/0000950170-25-107321.md) | [(0.80)](/filings/0001193125-25-277584.md) | not reported | [(1.03)](/filings/0001193125-26-219397.md) | [(0.97)](/filings/0001193125-26-344607.md) | [(0.85)](/filings/0001193125-25-277584.md) | not reported | [(0.66)](/filings/0001193125-26-219397.md) | [(0.63)](/filings/0001193125-26-344607.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating, us-gaap:InterestExpense
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [23.0](/filings/0000950170-24-126366.md) | [34.6](/filings/0000950170-25-046074.md) | [224](/filings/0000950170-25-070325.md) | [132](/filings/0000950170-25-107321.md) | [105](/filings/0001193125-25-277584.md) | [96.6](/filings/0001193125-26-126242.md) | [56.9](/filings/0001193125-26-219397.md) | [53.4](/filings/0001193125-26-344607.md) | [34.2](/filings/0001193125-25-277584.md) | [124](/filings/0001193125-26-344607.md) | [32.2](/filings/0001193125-26-219397.md) | [31.8](/filings/0001193125-26-344607.md) |
| Current assets | $m | not reported | [60.7](/filings/0000950170-25-046074.md) | [375](/filings/0000950170-24-059628.md) | [349](/filings/0000950170-24-095462.md) | [325](/filings/0000950170-24-126366.md) | [291](/filings/0001193125-26-126242.md) | [248](/filings/0000950170-25-070325.md) | [214](/filings/0000950170-25-107321.md) | [175](/filings/0001193125-25-277584.md) | [283](/filings/0001193125-26-344607.md) | [242](/filings/0001193125-26-219397.md) | [207](/filings/0001193125-26-344607.md) |
| Total assets | $m | not reported | [75.2](/filings/0000950170-25-046074.md) | [390](/filings/0000950170-24-059628.md) | [363](/filings/0000950170-24-095462.md) | [339](/filings/0000950170-24-126366.md) | [305](/filings/0001193125-26-126242.md) | [261](/filings/0000950170-25-070325.md) | [227](/filings/0000950170-25-107321.md) | [187](/filings/0001193125-25-277584.md) | [294](/filings/0001193125-26-344607.md) | [257](/filings/0001193125-26-219397.md) | [220](/filings/0001193125-26-344607.md) |
| Current liabilities | $m | not reported | [19.9](/filings/0000950170-25-046074.md) | [21.9](/filings/0000950170-24-059628.md) | [23.5](/filings/0000950170-24-095462.md) | [31.0](/filings/0000950170-24-126366.md) | [33.8](/filings/0001193125-26-126242.md) | [33.3](/filings/0000950170-25-070325.md) | [39.8](/filings/0000950170-25-107321.md) | [33.9](/filings/0001193125-25-277584.md) | [36.5](/filings/0001193125-26-344607.md) | [29.7](/filings/0001193125-26-219397.md) | [22.8](/filings/0001193125-26-344607.md) |
| Total liabilities | $m | not reported | [26.0](/filings/0000950170-25-046074.md) | [29.0](/filings/0000950170-24-059628.md) | [29.6](/filings/0000950170-24-095462.md) | [36.5](/filings/0000950170-24-126366.md) | [38.1](/filings/0001193125-26-126242.md) | [36.6](/filings/0000950170-25-070325.md) | [42.1](/filings/0000950170-25-107321.md) | [35.2](/filings/0001193125-25-277584.md) | [61.6](/filings/0001193125-26-344607.md) | [61.4](/filings/0001193125-26-219397.md) | [54.3](/filings/0001193125-26-344607.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [24.7](/filings/0001193125-26-344607.md) | not reported | [24.9](/filings/0001193125-26-344607.md) |
| Shareholders' equity | $m | [(112)](/filings/0000950170-24-126366.md) | [(13.1)](/filings/0001193125-26-126242.md) | [361](/filings/0001193125-25-277584.md) | [334](/filings/0001193125-25-277584.md) | [303](/filings/0001193125-25-277584.md) | [267](/filings/0001193125-26-344607.md) | [224](/filings/0001193125-26-344607.md) | [184](/filings/0001193125-26-344607.md) | [152](/filings/0001193125-25-277584.md) | [232](/filings/0001193125-26-344607.md) | [196](/filings/0001193125-26-344607.md) | [166](/filings/0001193125-26-344607.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.1) d](/filings/0000950170-24-126366.md) | [(18.6) d](/filings/0000950170-25-046074.md) | [(25.5)](/filings/0000950170-25-070325.md) | [(24.2) d](/filings/0000950170-25-107321.md) | [(27.5) d](/filings/0001193125-25-277584.md) | [(37.1) d](/filings/0001193125-26-126242.md) | [(44.9)](/filings/0001193125-26-219397.md) | [(31.9) d](/filings/0001193125-26-344607.md) | [(43.3) d](/filings/0001193125-25-277584.md) | [(33.5) d](/filings/0001193125-26-126242.md) | [(41.6)](/filings/0001193125-26-219397.md) | [(40.3) d](/filings/0001193125-26-344607.md) |
| Capital expenditure | $m | [0.3 d](/filings/0000950170-24-126366.md) | [0.3 d](/filings/0000950170-25-046074.md) | [0.5](/filings/0000950170-25-070325.md) | [1.0 d](/filings/0000950170-25-107321.md) | [0.1 d](/filings/0001193125-25-277584.md) | [0.5 d](/filings/0001193125-26-126242.md) | [0.0](/filings/0000950170-25-070325.md) | [0.0 d](/filings/0001193125-26-344607.md) | [0.0 d](/filings/0001193125-25-277584.md) | [(0.0) d](/filings/0001193125-26-126242.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.9](/filings/0000950170-24-059628.md) | [0.6](/filings/0000950170-24-095462.md) | [0.7](/filings/0000950170-24-126366.md) | [23.8](/filings/0000950170-25-070325.md) | [43.1](/filings/0000950170-25-107321.md) | [43.2](/filings/0001193125-25-277584.md) | [43.2](/filings/0001193125-26-219397.md) | [43.2](/filings/0001193125-26-344607.md) | [43.4](/filings/0001193125-25-277584.md) | [60.4](/filings/0001193125-26-219397.md) | [60.9](/filings/0001193125-26-344607.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,843,444 at 2026-08-03, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344607.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.